Medical treatment for sphincter of oddi dysfunction: Can it replace endoscopic sphincterotomy?

Véronique Vitton, Salah Ezzedine, Jean-Michel Gonzalez, Mohamed Gasmi, Jean-Charles Grimaud, Marc Barthet

Véronique Vitton, Salah Ezzedine, Jean-Michel Gonzalez, Mohamed Gasmi, Jean-Charles Grimaud, Marc Barthet, Department of Gastroenterology, Hôpital Nord, Chemin des Bourrely, 13915 Marseille cedex 20, France

Author contributions: Vitton V and Barthet M contributed to study concept and design, acquisition and interpretation of the data, drafting of the manuscript and critical and final revisions of the manuscript; Ezzedine S and Gasmi M contributed to acquisition and interpretation of the data and critical revision of the manuscript; Gonzalez JM contributed to acquisition and interpretation of the data and drafting of the manuscript; Grimaud JC contributed to study concept and design and critical revision of the manuscript.

Correspondence to: Veronique Vitton, MD, PhD, Department of Gastroenterology, Hôpital Nord, Chemin des Bourrely, 13915 Marseille cedex 20, France. vittonv@yahoo.com

Telephone: +33-4-91965598 Fax: +33-4-91965550

Received: April 18, 2011 Revised: June 16, 2011

Accepted: February 27, 2012 Published online: April 14, 2012

Abstract

AIM: To report the results of a medical management of sphincter of oddi dysfunction (SOD) after an intermediate follow-up period.

METHODS: A total of 59 patients with SOD (2 men and 57 women, mean age 51 years old) were included in this prospective study. After medical treatment for one year, the patients were clinically re-evaluated after an average period of 30 mo.

RESULTS: The distribution of the patients according to the Milwaukee’s classification was the following: 11 patients were type 1, 34 were type 2 and 14 were type 3. Fourteen patients underwent an endoscopic sphincterotomy (ES) after one year of medical treatment. The median intermediate follow-up period was 29.8 ± 3 mo (3-72 mo). The initial effectiveness of the medical treatment was complete, partial and poor among 50.8%, 13.5% and 35%, respectively, of the patients. At the end of the follow-up period, 37 patients (62.7%) showed more than 50% improvement. The rate of improvement in patients who required ES was not significantly different compared with the patients treated conservatively (64.2% vs 62.2%, respectively).

CONCLUSION: Our study confirms that conservative medical treatment could be an alternative to endoscopic sphincterotomy because, after an intermediate follow-up period, the two treatments show the same success rates.

© 2012 Baishideng. All rights reserved.

Key words: Sphincter of oddi dysfunction; Cholecystectomy; Endoscopic sphincterotomy; Biliary scintigraphy

INTRODUCTION

Sphincter of oddi dysfunction (SOD) is a functional gastrointestinal abnormality characterized by pancreaticobiliary pain that can be debilitating and may impair the quality of life. The cause of SOD remains speculative, but it could be due to hormonal or neurological disturbances of the sphincter of oddi (SO), leading to its intermittent obstruction despite the absence of organic
abnormalities. The best way to establish diagnosis and manage SOD remains controversial, mainly in SOD type 2 and 3 of the Milwaukee classification. The diagnosis of SOD is usually based on a high index of clinical suspicion. Direct endoscopic manometry of the SO is an invasive procedure that remains the gold standard for the diagnosis of SOD. However, dynamic biliary scintigraphy has been used as a non-invasive tool for evaluation of the SO by providing indirect evidence of increased sphincter resistance. The contribution of the biliary scintigraphy appears to predict, with good effectiveness, the clinical success of biliary endoscopic sphincterotomy in SOD types 1 and 2 of the Milwaukee classification. The management of SOD is also controversial, and it is based on the relaxation of the SO, which should improve the symptoms of SOD. The treatment can be accomplished pharmaco logically either by an endoscopic procedure or surgically. The surgical procedure is often replaced by an endoscopic procedure. Several studies have suggested that there is a benefit from endoscopic sphincterotomy (ES) in SOD patients having high SO basal pressures at the time of manometry. However, procedural pancreatitis cannot be completely avoided, and surgical treatment will be necessary in some cases. Morbidity and mortality after ES have been reported to be as high as 9.8% and 2.3%, respectively. Moreover, long-term data regarding the rate of restenosis and complications resulting from repeated therapy are limited. If SO manometry findings are abnormal, the relief of pain after sphincterotomy occurs in 90%-95% of patients with type 1 SOD, 85% of patients with type 2 SOD, and 55%-60% of patients with type 3 SOD. However, almost uniformly and despite ES, some patients continue to have pain that is consistent with nonspecific chronic pain disorders, suggesting a multifactorial cause for SOD. Endoscopic stenting is no longer recommended as a routine method of treatment of SOD because endoscopic stenting is associated with poor symptomatic relief and a high risk of stent-induced pancreatitis. Many pharmacologic agents that are known to relax the SO have already been used in the management of SOD. However, although medical therapy may be an attractive initial approach in patients with sphincter of Oddi dysfunction, data on intermediate clinical outcomes associated with pharmacological treatment is scant. In a recent study, we showed that a one-year treatment period with trimebutine could significantly reduce pain in patients suffering from SOD, reducing the need for ES. Our aim in the current study was to determine the efficacy of medical therapy in relieving symptoms of SOD compared to ES after a prolonged follow-up period.

MATERIALS AND METHODS

As described in our previous study, fifty-nine patients complaining of SOD were included in this prospective monocentric study between 1999 and 2005. The patients included 57 women and 2 men, with a mean age of 50.5 ± 12.3 years old (range 20-75 years old), which were followed for a mean duration of 29 mo after the end of the endoscopic or medical treatment. The main inclusion criterion was biliary or pancreatic pain after cholecystectomy after ruling out the diagnosis of residual lithi asis or the presence of a tumor. The following data were collected: age, sex, cholecystectomy, the time elapsing since the onset of the symptoms, pain and rate of SOD occurrence. All of the patients underwent biliary or pancreatic endoscopic ultrasonography in order to rule out the diagnosis of a residual lithi asis or the presence of a tumor (none of the patients underwent secretin-magnetic resonance cholangiopancreatography). The diameters of the main biliary pathway and the canal de Wirsung were systematically measured during these procedures. An initial biological check-up was carried out when the first painful episode occurred after the medical consultation. The biological check-up included the measurement of the following proteins: transaminases (alanine aminotransferase and aspartate aminotransferase), gamma-glutamyltransferase, alkaline phosphatases, total and conjugate bilirubin, amylase and lipase. PD-SOD was defined as the association between recurrent pancreatic pain with an increased level of serum lipase (> 3N). An initial biliary scintigraphy was carried out systematically on all of the patients. An initial hepatic and pancreatic biological assessment was done at the first event of abdominal pain. In addition, a biliary scintigraphy was performed for all patients in order to determine the isotopic hile to duodenum transit time (HDTT). According to the Milwaukee classification of SOD, the patients were subdivided into three groups. All of the patients were clearly informed about the various therapeutic modalities to manage their disease, the chances of success and the rates of complications of the medical therapy or endoscopic treatment. For each patient, we proposed an initial management of SOD by medical treatment, planned for a one-year duration; it consisted of a combined treatment, an association of trimebutine (200 mg three times per day) and nitrates taken sublingually when needed, mainly at the onset of abdominal pain. In the case of intolerance or counter-indication to the nitrates, a treatment with trimebutine alone was proposed. If previous treatment with trimebutine had been unsuccessful, only the nitrates derivatives were prescribed. If the painful attacks occurred too frequently (> 1 per week), a transdermal nitrate treatment (5 mg/d) was prescribed. The patients attended clinical follow-up consultations every four mo for a period of one year. After one year of medical therapy, an evaluation of painful symptoms was performed for each patient. The efficacy of the treatment was considered complete if there was a complete disappearance of the painful symptoms; the efficacy was considered partial if there was a greater than 50% reduction in the frequency and intensity of the pain and considered poor when the frequency and intensity of the pain decreased by less than 50%. In the cases where the medical treat-
The management was only partially successful or poor, endoscopic sphincterotomy was proposed to the patients, but not to the remaining patients. If medical treatment was successful, endoscopic treatment was not proposed. When the indications for endoscopic treatment had been chosen, the patients received clear information concerning the procedure. The endoscopic treatment was performed under general anaesthesia and consisted of an endoscopic retrograde cholangiopancreatography, with realization of a biliary sphincterotomy on patients with isolated biliary symptoms or dual sphincterotomy (biliary and pancreatic) on patients with both biliary and pancreatic symptoms. All of the patients were called by telephone to propose a follow-up examination with a hepatic biological assessment and an abdominal ultrasound in order to measure the diameter of the main biliary and pancreatic ducts; among these patients, only 3 had a lengthening of the isotopic transit time of transit was present before the ES in 11 patients of the 14 who underwent this intervention (78.5%) and 42 patients had a combined treatment of nitrates and trimebutine (71.1%). The mean duration of the treatment period was 11.5 ± 0.8 mo. The efficacy of the medical therapy was considered to be complete or partial in 38 patients (64.3%) and poor in 21 patients (35%). Details concerning the success of the medical treatment are presented in Table 2. Among the 21 patients with poor results from the medical management, 14 (23.7%) agreed to undergo ES, including 12 with an isolated biliary sphincterotomy and 2 with an associated pancreatic sphincterotomy (dual sphincterotomy). In patients with a dual sphincterotomy, a pancreatic duct stenting was performed. A lengthening of the isotopic time of transit was present before the ES in 11 patients of the 14 who underwent this intervention (78.5%) and in 21 patients of the 45 without ES (46.6%) (P = 0.02). Other characteristics concerning ES are presented in Table 3. The complications of the ES were severe acute pancreatitis in two cases, which had resolved favourably with medical treatment. Among the patients requiring an ES, three patients had mixed biliary and pancreatic symptoms, and 9 patients had an isolated pancreatic pattern; among these patients, only 3 had a lengthening of the HDTT on the biliary scintigraphy corresponding to the 3 patients with isolated pancreatic symptoms as defined in the Materials and Methods section.

**Intermediate follow-up period**

Five patients refused to participate in the follow-up period. The intermediate follow-up period was 29.8 ± 3 mo (3-72 mo). Thirty-seven patients either did not present any other symptoms or the symptoms were not severe enough to require follow-up. The patients developed the symptoms of SOD after a mean period of 9.3 ± 1.2 years (range, 1-38 years) after the cholecystectomy. The patient’s main characteristics are presented in Table 1. According to the three Milwaukee groups, there were no significant differences in age (type 1, 56.2 ± 2.1 years old; type 2, 48.1 ± 2.1 years old; and type 3, 52.1 ± 3.5 years old, P = 0.22) or the time elapsing from diagnosis to the cholecystectomy (type 1, 11 ± 3.6 years; type 2, 8.6 ± 1.6 years; and type 3, 10 ± 2.4 years; P = 0.93). Five patients were treated with nitrates only (8.4%), 12 were treated with trimetubine only (20.3%), and 42 patients had a combined treatment of nitrates and trimetubine (71.1%).

### Statistical analysis

Statistical analysis was carried out on the data with the Statview software program (Abacus concept, Inc., Berkeley, CA, 1992). Quantitative data were expressed as the mean ± SD. The significance of the differences was tested using the Student’s t test or paired t tests to make comparisons between groups. Nonparametric tests (Mann Whitney tests) were performed when the Student’s t test was not appropriate. The qualitative variables were compared using the chi-square test with Yates’s correction when appropriate and with Fisher’s exact test for 2 × 2 contingency tables. The significance threshold was set at P < 0.05.

### RESULTS

#### Characteristics of the SOD and treatment

The patients developed the symptoms of SOD after a mean period of 9.3 ± 1.2 years (range, 1-38 years) after the cholecystectomy. The patient’s main characteristics are presented in Table 1. According to the three Milwaukee groups, there were no significant differences in age (type 1, 56.2 ± 2.1 years old; type 2, 48.1 ± 2.1 years old; and type 3, 52.1 ± 3.5 years old, P = 0.22) or the time elapsing from diagnosis to the cholecystectomy (type 1, 11 ± 3.6 years; type 2, 8.6 ± 1.6 years; and type 3, 10 ± 2.4 years; P = 0.93). Five patients were treated with nitrates only (8.4%), 12 were treated with trimetubine only (20.3%), and 42 patients had a combined treatment of nitrates and trimetubine (71.1%). The mean duration of the treatment period was 11.5 ± 0.8 mo. The efficacy of the medical therapy was considered to be complete or partial in 38 patients (64.3%) and poor in 21 patients (35%). Details concerning the success of the medical treatment are presented in Table 2. Among the 21 patients with poor results from the medical management, 14 (23.7%) agreed to undergo ES, including 12 with an isolated biliary sphincterotomy and 2 with an associated pancreatic sphincterotomy (dual sphincterotomy). In patients with a dual sphincterotomy, a pancreatic duct stenting was performed. A lengthening of the isotopic time of transit was present before the ES in 11 patients of the 14 who underwent this intervention (78.5%) and in 21 patients of the 45 without ES (46.6%) (P = 0.02). Other characteristics concerning ES are presented in Table 3. The complications of the ES were severe acute pancreatitis in two cases, which had resolved favourably with medical treatment. Among the patients requiring an ES, three patients had mixed biliary and pancreatic symptoms, and 9 patients had an isolated pancreatic pattern; among these patients, only 3 had a lengthening of the HDTT on the biliary scintigraphy corresponding to the 3 patients with isolated pancreatic symptoms as defined in the Materials and Methods section.

#### Table 1  Patient’s characteristics a (%)

| Characteristic                  | n (% of the group) |
|--------------------------------|--------------------|
| Age, mean ± SD, yr             | 50.5 ± 12          |
| Sex, M/F                       | 2/57               |
| Symptoms                       |                    |
| Biliary                        | 47 (79.6)          |
| Pancreatic                     | 9 (15.2)           |
| Biliopancreatic                | 3 (5)              |
| Occurrence of painful episodes |                    |
| Once a week                    | 9 (15.8)           |
| Once a month                   | 20 (35.1)          |
| Every 3 mo                     | 9 (15.8)           |
| Every 6 mo                     | 3 (5.3)            |
| Once a year                    | 7 (12.3)           |
| Dilatation of biliary or pancreatic ducts (bile duct > 12 mm; pancreatic duct > 4 mm) | |
| Main biliary duct dilatation 29 (49.1) | |
| Main pancreatic duct dilatation 1 (1.7) | |
| Milwaukee classification repartition |               |
| Type 1                         | 11 (18.6)          |
| Type 2                         | 34 (57.6)          |
| Type 3                         | 14 (23.7)          |
| Initial elevation of laboratory data | 34 (57.6) | |
| Lengthening of the isotopic transit time | 32 (54.2) | |

#### Table 2 One-year outcome after medical treatment a (%)

| Global effect                          | n (%)     | P      |
|----------------------------------------|-----------|--------|
| Complete or partial                    | 38 (64.3) |        |
| Poor                                   | 21 (35)   | < 0.05 |
| Complete or partial effect according the Milwaukee group |           |        |
| Type 1                                 | 5 (45)    |        |
| Type 2                                 | 23 (67)   | 0.31   |
| Type 3                                 | 10 (71)   |        |
| Without prolongation of HDTT           | 21 (55.3) |        |

HDTT: Hile to duodenum transit time.
ent any additional painful events or improved by more than 50% (62.7%). Twenty-two patients still presented painful episodes (38.6%). The characteristics of the patients following endoscopic treatment are presented in Table 3. An abdominal ultrasound was performed in 45 patients and highlighted a dilation of the main biliary duct in 10 patients (22%). A biological laboratory assessment was also performed in these 45 patients. Among these patients, 6 still presented abnormal liver and pancreatic enzyme serum levels. At the end of the follow-up period, there was no significant difference in the size of the main biliary duct (at the beginning of the study, 49% of patients had dilation, and at the end of the study, 22% still had dilation of the main biliary duct) ($P = 0.49$); these characteristics are presented in Table 4.

**DISCUSSION**

The present study demonstrates that medical management with trimebutine may improve pain in patients suffering from SOD. Moreover, our study shows that after an intermediate follow-up period, the success of medical treatment (62%) does not differ from that of ES (64%). The medical treatment of SOD is usually disappointing, although nitrates or calcium-channel blockers can decrease basal pressure of the SO [32-34]. A positive effect of erythromycin on the motility of the SO has been suggested, but its clinical efficacy has not been demonstrated [35]. Somatostatin also modifies the SO activity but in the direction of an increase in the frequency of the phasic contractions of basal pressure. Therefore, somatostatin would be of little benefit for the indication of SOD and would not be suitable as a preventive measure after endoscopic retrograde cholangiopancreatography. The injection of botulinum toxin within the sphincter was tested in humans and pigs and provided a significant reduction in the basal pressure in 50% of the cases [36-41]. On the clinical level, the injection of botulinum toxin was beneficial in 55% of the patients who suffered from biliary pain post-cholecystectomy without disturbance of the hepatic enzymes or dilation of the bile duct. However, 90% of the patients who experienced improvement presented a recurrence of symptoms after 6 mo, making the effect of botulinum toxin inconstant and transitory [37-41]. Endoscopic management is mainly based on the ES, requiring SOD diagnosis to be formally established, i.e., based on the description of a basal high pressure of the SO. However, despite its high rate of success (86%-91%), ES is associated with high morbidity (19%-30%). Moreover, the natural course of SOD has not been well documented so far, so that the use of this endoscopic strategy remains highly controversial [42-49].

Our research group previously described the effects of trimebutine on Oddi motility in a prospective study on patients with post-cholecystectomy pain [29]. We also reported in another study [32] that a one-year medical management could avoid the need for ES and had a success rate of 64%. Kovács et al. [31] previously suggested that, depending on the Milwaukee classification, medical treatment should be first attempted and its efficacy subsequently reassessed; if this treatment fails or is poorly tolerated, ES can then be proposed, especially for type 1 or 2 SOD patients, based on the presence of a lengthening of the HDTT. The lengthening of the HDTT as a factor for predicting a favourable response to ES decreases with the Milwaukee types, as mentioned by Cicala et al. [17]. In our study, 100% of the type 1 patients, 78% of the type 2 patients and none of the type 3 patients showed a lengthening of the HDTT and underwent ES successfully, whereas the immediate efficacy of ES was only 86%. This ES success rate is quite similar to the success rate reported in the literature, which ranged between 86% and 91% [18,30-32]. Few studies have addressed the intermediate natural history of SOD. The available data suggest that the clinical course is variable depending, in part, on the initial biliary classification. In a one-year follow-up study, seven SOD type 2 patients with abnormal SO pressure treated by a sham procedure continued to have symptoms, which ended only after subsequent ES. All patients continued to do well four years later. Five other SOD type 2 patients with abnormal SO pressure refused ES; after four years, three were unimproved while two had “fair” improvement. The clinical course was unpredictable after a sham or ES treatment in patients with SOD type 3 biliary pain. In another report, 11 such patients were followed for two years after ES. Four improved symptomatically, while

| Table 3 Results of the endoscopic treatment ($n = 14$), (%) |
|---------------------------------------------------------|
| Time between the beginning of medical therapy and endoscopic treatment (mo) | 12.2 ± 1.5 |
| Patients concerned | 12 (57.1) |
| Patients with poor response to medical treatment | 2 (25) |
| Indication according to Milwaukee group | |
| Type 1 | 4 (36) |
| Type 2 | 9 (27) |
| Type 3 | 1 (7) |
| Results according to Milwaukee group | |
| Type 1 | 3/4 (75) |
| Type 2 | 6/9 (66) |
| Type 3 | 0/1 (0) |

| Table 4 Results after intermediate follow-up (29.8 ± 3 mo) |
|---------------------------------------------------------|
| Rate of improvement | |
| Total rate | 37 (62.7) |
| Without endoscopic sphincterotomy | 28 (62) |
| With endoscopic sphincterotomy | 9 (64.2) |
| According to initial lengthening of HDTT | |
| With lengthening | 19 (59.4) |
| Without lengthening | 18 (66.7) |
| According to the Milwaukee group | |
| Type 1 | 6/11 (54.5) |
| Type 2 | 23/34 (67.6) |
| Type 3 | 8/14 (57.1) |

HDTT: Hile to duodenum transit time.
seven had no change in their symptoms. Eleven other patients had a sham procedure, five of which improved, while six had no change in their symptoms during a two-year follow-up period[3]. In our study, the monitoring of the response rate to ES after an average period of 29 mo showed a loss of efficacy of the ES in 3 patients. Therefore, the rate of patient improvement did not differ significantly in the presence or absence of a previous ES according to the performance or not of an ES.

In conclusion, our study confirms that a conservative medical treatment could be an alternative to ES because, after an intermediate follow-up period, the two treatments show the same success rates.

REFERENCES

1 Lehman GA, Sherman S. Sphincter of Oddi dysfunction. Int J Pancreatol 1996; 20: 11-25
2 Black NA, Thompson E, Sanderson CF. Symptoms and health status before and after six weeks of open choledochectomy: a European cohort study. ECHSS Group. European Collaborative Health Services Study Group. Gut 1994; 35: 1301-1305
3 Chittur R, Carr-Locke DL. Pathophysiology of the sphincter of Oddi. Surg Clin North Am 1993; 73: 1311-1322
4 DeSautels SG, Slivka A, Hutson WR, Chun A, Mitra C, DiLorenzo C, Wald A. Postcholecystectomy pain syndrome: pathophysiology of abdominal pain in sphincter of Oddi type III. Gastroenterology 1999; 116: 900-905
5 Bar-Meir S, Halpern Z, Bardan E, Gilat T. Frequency of papillary dysfunction among cholecystectomized patients.

**Hepatology** 1984; 4: 328-330

6 Tzovaras G, Rowlands BJ. Diagnosis and treatment of sphincter of Oddi dysfunction. Br J Surg 1998; 85: 588-595

7 Petersen BT. An evidence-based review of sphincter of Oddi dysfunction: part I, presentations with “objective” biliary findings (types I and II). Gastrointest Endosc 2004; 59: 525-534

8 Hawes RH, Tarnasky PR. Endoscopic manometry of the sphincter of Oddi: its usefulness for the diagnosis and treatment of benign papillary stenosis. Gastrointest Endosc 1996; 43: 536-538

9 Hogan WJ, Sherman S, Pasricha P, Carr-Locke D. Sphincter of Oddi manometry. Gastrointest Endosc 1997; 45: 342-348

10 Fullarton GM, Allan A, Hilditch T, Murray WR. Quantitative 99mTc-DISIDA scanning and endoscopic biliary manometry in sphincter of Oddi dysfunction. Gut 1988; 29: 1397-1401

11 Rosenblatt ML, Catalano MF, Alcocer E, Geenen JE. Comparison of sphincter of Oddi manometry, fatty meal sonography, and hepatobiliary scintigraphy in the diagnosis of sphincter of Oddi dysfunction. Gastrointest Endosc 2001; 54: 697-704

12 Sherman S. What is the role of ERCP in the setting of abdominal pain of pancreatic or biliary origin (suspected sphincter of Oddi dysfunction)? Gastrointest Endosc 2002; 56: S258-S266

13 Sherman S, Lehman GA. Sphincter of Oddi dysfunction: diagnosis and treatment. JOP 2001; 2: 382-400

14 Nussbaum MS, Warner BW, Sax HC, Fischer JE. Transduodenal sphincteroplasty and transampullary septectomy for primary sphincter of Oddi dysfunction. Am J Surg 1989; 157: 38-43

15 Anderson TM, Pitt HA, Longmire WP. Experience with sphincteroplasty and sphincterotomy in pancreatobiliary surgery. Ann Surg 1985; 201: 399-406

16 Tzovaras G, Rowlands BJ. Transduodenal sphincteroplasty and transampullary septectomy for sphincter of Oddi dysfunction. Ann R Coll Surg Engl 2002; 84: 14-19

17 Cicala M, Habib FI, Vavassori P, Pallotta N, Schillaci O, Costamagna G, Guarino M, Scopinaro F, Fiocca F, Torsoli A, Corazziari E. Outcome of endoscopic sphincterotomy in post cholecystectomy patients with sphincter of Oddi dysfunction as predicted by manometry and quantitative cholestochocystigraphy. Gut 2002; 50: 665-668

18 Geenen JE, Hogan WJ, Dodds WJ, Toouli J, Venu RP. The efficacy of endoscopic sphincterotomy after cholecystectomy in patients with sphincter-of-Oddi dysfunction. N Engl J Med 1989; 320: 82-87

19 Neoptolemos JP, Bailey IS, Carr-Locke DL. Sphincter of Oddi dysfunction: results of treatment by endoscopic sphincterotomy. Br J Surg 1988; 75: 454-459

20 Goff JS. Common bile duct sphincter of Oddi stenting in patients with suspected sphincter dysfunction. Am J Gastroenterol 1995; 90: 586-589

21 Kovács F, Győkeres T, Elek G, Pap A. [Sphincter of Oddi dysfunction—prolonged medical therapy or early endoscopic sphincter ablation]. Orv Hetil 2002; 143: 2829-2834

22 Pasrichia PJ, Miskovsky EP, Kalloo AN. Intraspincteric injection of botulinum toxin for suspected sphincter of Oddi dysfunction. Gut 1994; 35: 1319-1321

23 Lee SK, Kim MH, Kim HJ, Seo DS, Yoo KS, Joo YH, Min YI, Kim JH, Min BI. Electroacupuncture may relax the sphincter of Oddi in humans. Gastroenterol 2001; 53: 211-216

24 Guelrud M, Fossler A, Souney PF, Mendoza S, Mujica V. The effect of transcutaneous nerve stimulation on sphincter of Oddi pressure in patients with biliary dyskinesia. Am J Gastroenterol 1991; 86: 581-585

25 Di Francesco V, Angelini G, Bovo P, Casarini MB, Filippini M, Vaona B, Frulloni L, Rigo L, Brunori MP, Cavallini G. Effect of ocetride on sphincter of Oddi motility in patients

COMMENTS

**Background**

Sphincter of Oddi dysfunction (SOD) is a symptom characterized by recurrent abdominal pain. It has been showed that and endoscopic treatment called endoscopic sphincterotomy (ES) can improve symptoms but with a high level of complications. Pharmacologic agents have been tested in this pathology but are still disappointing.

**Research frontiers**

Many ways of treatment (medical, endoscopic) are still studied because none of them offer a satisfying and safe rate of prolonged improvement.

**Innovations and breakthroughs**

The authors here demonstrate that, after a long follow-up (29 mo), a medical treatment with trimebutine can have the same success rate than ES.

**Applications**

The demonstration of a long-term efficacy of a medical conservative treatment is important because it can avoid the need for ES which is associated with morbidity and mortality after ES of 9.8% and 2.3% respectively. This study demonstrates that a medical conservative treatment with trimebutine may be an effective alternative to the endoscopic sphincterotomy since, after an intermediate follow-up, the two treatments show the same success rate.

**Terminology**

The sphincter of Oddi is a muscular valve that controls the flow of digestive juices (bile and pancreaticjuice) through the ampulla of Vaterinto the second part of the duodenum. ES is an endoscopic technique developed to examine and treat abnormalities of the bile ducts, pancreas and gallbladder. The procedure as developed as an extension to the diagnostic examination, endoscopic retrograde cholangio-pancreatography; with the addition of “sphincterotomy”, abnormalities found during the study could be treated at the same time without the need for invasive surgery.

**Peer review**

This study is about the results of a medical management of SOD after an intermediate follow-up. It is well-written.
with acute recurrent pancreatitis: a manometric study. Dig Dis Sci 1996; 41: 2392-2396

26 Bar-Meir S, Halpern Z, Bardan E. Nitrate therapy in a patient with papillary dysfunction. Am J Gastroenterol 1983; 78: 94-95

27 Binnouiller KF, Dumas R, Harris AG, Delmont JP. Effect of somatostatin analog octreotide on human sphincter of Oddi. Dig Dis Sci 1992; 37: 773-777

28 Craig AG, Totttrup A, Touliu J, Saccone GT. Relative effects of dihydroxypridine type-L calcium channel antagonism on biliary, duodenal, and vascular tissues: an in vivo and in vitro analysis in Australian brush-tailed possum. Dig Dis Sci 2002; 47: 2029-2036

29 Barthet M, Bouvier M, Pecout C, Berdah S, Viviand X, Mambrini P, Abou E, Salducci J, Grimaud JC. Effects of trimetubine on sphincter of Oddi motility in patients with post-cholecystectomy pain. Aliment Pharmacol Ther 1998; 12: 647-652

30 Wehrmann T, Pfeitzer C, Caspary WF. Effect of erythromycin on human biliary motility. Aliment Pharmacol Ther 1996; 10: 421-426

31 Cheon YK, Cho YD, Moon JH, Im HH, Jung Y, Lee JS, Lee MS, Shim CS. Effects of vardenafil, a phosphodiesterase type-5 inhibitor, on sphincter of Oddi motility in patients with suspected biliary sphincter of Oddi dysfunction. Gastrointest Endosc 2009; 69: 1111-1116

32 Vitton V, Delpy R, Gasmi M, Lesavre N, Abou-Berdugo E, Desjeux A, Grimaud JC, Barthet M. Is endoscopic sphincterotomy avoidable in patients with sphincter of Oddi dysfunction? Eur J Gastroenterol Hepatol 2008; 20: 15-21

33 Maldonado ME, Brady PG, Mamel J, Robinson B. Incidence of pancreatitis in patients undergoing sphincter of Oddi manometry (SOM). Am J Gastroenterol 1999; 94: 387-390

34 Singh P. Is sphincter of Oddi manometry a risk factor for pancreatitis? A different view. Curr Gastroenterol Rep 2005; 7: 141-146

35 Singh P, Gurudoo SR, Davidoff S, Sivak MV, Indaram A, Kasmin FE, Nozak V, Wong RC, Isenberg G, Stark B, Bank S, Chak A. Sphincter of Oddi manometry does not predispose to post-ERCPC acute pancreatitis. Gastrointest Endosc 2004; 59: 499-505

36 Evans PR, Dowsett JF, Bak YT, Chan YK, Kellow JE. Abnormal sphincter of Oddi response to cholecystokinin in postcholecystectomy syndrome patients with irritible bowel syndrome. The irritable sphincter. Dig Dis Sci 1995; 40: 1149-1156

37 Wehrmann T, Seifert H, Seipp M, Lembcke B, Caspary WF. Endoscopic injection of botulinum toxin for biliary sphincter of Oddi dysfunction. Endoscopy 1998; 30: 702-707

38 Sand J, Nordback I, Arvola P, Pösäti I, Kalloa A, Pasricha P. Effects of botulinum toxin A on the sphincter of Oddi: an in vivo and in vitro study. Gut 1998; 42: 507-510

39 Fazel A, Li SC, Burton FR. Octreotide relaxes the hypertensive sphincter of Oddi: pathophysiologically and therapeutically. Am J Gastroenterol 2002; 97: 612-616

40 Khuroo MS, Zargar SA, Yattoo GN. Efficacy of nifedipine therapy in patients with sphincter of Oddi dysfunction: a prospective, double-blind, randomized, placebo-controlled, cross over trial. Br J Clin Pharmacol 1992; 33: 477-485

41 Guerlud M, Mendoza S, Rosset G, Ramirez L, Barkin J. Effect of nifedipine on sphincter of Oddi motor activity: studies in healthy volunteers and patients with biliary dyskinesia. Gastroenterology 1988; 95: 1050-1055

42 Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, Moore JP, Fennerty MB, Ryan ME, Shaw MJ, Lande JD, Phelley AM. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335: 909-918

43 Masci E, Toti C, Mariani A, Curioni S, Lonazotti A, Dinelli M, Minoli G, Crosta C, Comin U, Fertiitta A, Prada A, Pasoni GR, Testoni PA. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 2001; 96: 417-423

44 Barthet M, Lesavre N, Desjeux A, Gasmi M, Berthezene P, Berdah S, Viviand X, Grimaud JC. Complications of endoscopic sphincterotomy: results from a single tertiary referral center. Endoscopy 2002; 34: 991-997

45 Barthet M, Heyries L, Desjeux A. [Short term complications of endoscopic retrograde cholangiopancreatography]. Gastroenterol Clin Biol 2002; 26: 980-987

46 Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, Overby CS, Aas J, Ryan ME, Bochma GS, Shaw MJ, Snady HW, Erickson RV, Moore JP, Roel JP. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54: 425-434

47 Corazziari E, Shaffer EA, Hogan WJ, Sherman S, Touli J. Functional disorders of the biliary tract and pancreas. Gut 1999; 45 Suppl 2: II84-II85

48 Chen JW, Saccone GT, Touliu J. Sphincter of Oddi dysfunction and acute pancreatitis. Gut 1998; 43: 305-308

49 Touli J, Roberts-Thomson IC, Kellow J, Dowsett J, Saccone GT, Evans P, Jeans P, Cox M, Anderson P, Worthley C, Chan Y, Shanks N, Craig A. Manometry based randomised trial of endoscopic sphincterotomy for sphincter of Oddi dysfunction. Gut 2000; 46: 98-102

50 Petersen BT. Sphincter of Oddi dysfunction, part 2: Evidence-based review of the presentations, with “objective” pancreatic findings (types I and II) and of presumptive type III. Gastroenterol 2004; 59: 670-687

51 Park SH, Watkins JL, Fogel EL, Sherman S, Lazzell L, Buck-Sot L, Lehman GA. Long-term outcome of endoscopic dual pancreatobiliary sphincterotomy in patients with manometry-documented sphincter of Oddi dysfunction and normal pancreatogram. Gastrointest Endosc 2003; 57: 483-491

52 Touli J, Di Francesco V, Saccone G, Kollias J, Schlotthe A, Shanks N. Division of the sphincter of Oddi for treatment of dysfunction associated with recurrent pancreatitis. Br J Surg 1996; 83: 1205-1210

53 Botoman VA, Kozarek RA, Novell LA, Patterson DJ, Ball TJ, Wechter DG, Neal LA. Long-term outcome after endoscopic sphincterotomy in patients with biliary colic and suspected sphincter of Oddi dysfunction. Gastrointest Endosc 1994; 40: 165-170